Board Meetings for BLISSGVS

Detailed list of historic and upcoming board meetings.

SymbolCompanyMeeting DatePurposeDescriptionLinks
BLISSGVSBliss GVS Pharma Limited12 May 2026Financial Results/Dividend/Other business mattersTo consider and approve the financial results for the period ended March 31, 2026, dividend and other business matters
BLISSGVSBliss GVS Pharma Limited12 May 2026Board Meeting IntimationBLISS GVS PHARMA LIMITED has informed the Exchange about Board Meeting to be held on 12-May-2026 to consider and approve the Yearly Audited Financial results of the Company for the period ended March 2026 and Dividend.
BLISSGVSBliss GVS Pharma Limited10 Feb 2026Financial Results/DividendTo consider and approve the Unaudited financial results for the period ended December 31, 2025 and the interim dividend, if any, for the financial year 2025-2026
BLISSGVSBliss GVS Pharma Limited10 Feb 2026Board Meeting IntimationBLISS GVS PHARMA LIMITED has informed the Exchange about Board Meeting to be held on 10-Feb-2026 to consider and approve the Quarterly Unaudited Financial results of the Company for the period ended December 2025 and Dividend.
BLISSGVSBliss GVS Pharma Limited06 Nov 2025Board Meeting IntimationBLISS GVS PHARMA LIMITED has informed the Exchange about Board Meeting to be held on 06-Nov-2025 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2025 .
BLISSGVSBliss GVS Pharma Limited06 Nov 2025Financial ResultsTo consider and approve the Unaudited Standalone and Consolidated financial results for the quarter and half year ended September 30, 2025
BLISSGVSBliss GVS Pharma Limited29 Jul 2025Financial ResultsTo consider and approve the financial results for the period ended Jun 30, 2025
BLISSGVSBliss GVS Pharma Limited29 Jul 2025Board Meeting IntimationBLISS GVS PHARMA LIMITED has informed the Exchange about Board Meeting to be held on 29-Jul-2025 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended June 2025 .
BLISSGVSBliss GVS Pharma Limited12 May 2025Other business mattersIntimation of Board Meeting to consider Issuance of Sweat Equity Shares.
BLISSGVSBliss GVS Pharma Limited12 May 2025Board Meeting IntimationBLISS GVS PHARMA LIMITED has informed the Exchange about Board Meeting to be held on 12-May-2025 to consider and approve the Yearly Audited Financial results of the Company for the period ended March 2025 and Dividend.
BLISSGVSBliss GVS Pharma Limited12 May 2025Financial Results/DividendTo consider and approve the financial results for the period ended March 31, 2025 and dividend
BLISSGVSBliss GVS Pharma Limited28 Jan 2025Financial Results/Other business mattersInter alia to consider, approve and take on record: 1. The Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2024; and2. The proposal for issuance of Sweat Equity Shares pursuant to applicable provisions of the Companies Act, 2013, the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 and other applicable laws and regulations to Key Managerial Personnel and/or Senior Management Personnel and/or Employee(s) of the Company including determination of the issue price if any, subject to such regulatory and statutory approvals as may be required including approval of the shareholders of the Company.
BLISSGVSBliss GVS Pharma Limited28 Jan 2025Board Meeting IntimationBLISS GVS PHARMA LIMITED has informed the Exchange about Board Meeting to be held on 28-Jan-2025 to consider and approve the Quarterly Unaudited Financial results of the Company for the period ended December 2024 and Other business.
BLISSGVSBliss GVS Pharma Limited24 Oct 2024BLISS GVS PHARMA LIMITED has informed the Exchange about Board Meeting to be held on 24-Oct-2024 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2024 .Board Meeting Intimation
BLISSGVSBliss GVS Pharma Limited24 Oct 2024Financial Results/Other business mattersTo consider and approve the financial results for the period ended September 30, 2024 and other business matters
Showing page 1 of 6 (78 total items)
Next